- AdventHealth
On Dec. 11, 2020, the U.S. Food and Drug Administration (FDA) announced an emergency use authorization (EUA) for a COVID-19 vaccine developed by Pfizer. An EUA allows for lifesaving medical products to become available during public health emergencies after a rigorous review of scientific evidence and extensive clinical trials proving that the product’s benefits outweigh its known and potential risks.
This authorization means the vaccine can begin its initial limited distribution to the highest risk populations, beginning with health care workers whose roles involve high exposure risk and includes older adults living in long-term care facilities. The vaccine will not initially be available to the general public.
According to the EUA granted by the FDA, the Pfizer vaccine’s clinical trials included approximately 44,000 participants who voluntarily received the vaccine and were closely monitored to measure the vaccine’s safety and effectiveness. These clinical trials have shown the vaccine to be safe and more than 90% effective with no serious side effects.
Full FDA approval of a COVID-19 vaccine requires the completion of all three phases of clinical trials and the submission of exhaustive data that demonstrates its safety and effectiveness.
In preparation for the EUA and potential FDA approval of a vaccine, the AdventHealth COVID-19 Vaccine Task Force has assembled leaders and experts across all areas of the organization to coordinate the clinical and logistical components of each vaccination phase. Each phase of the vaccine’s initial rollout is prioritized by the level of exposure risk and vulnerability to the coronavirus, starting with health care workers and older adults living in long-term care facilities.
“The announcement of this EUA is a significant step in a journey to accrue more tools that help us protect people from COVID-19,” said David Moorhead, MD, chief clinical officer for AdventHealth. “The detailed, publicly available data on this vaccine shows that it can safely and effectively save lives.”
As subsequent phases of the vaccine’s rollout continue toward its eventual availability to the general public, it is imperative to rely only on evidence-based information when making decisions about the COVID-19 vaccine. To help mitigate the pandemic and keep communities safe, the public is urged to take all the proper precautions to protect themselves and others, while being careful to avoid misinformation that can contribute to vaccine hesitancy and high-risk behaviors that can increase potential exposure to the virus.
Recent News
AdventHealth President and CEO Terry Shaw has been named one of Modern Healthcare’s 100 Most Influential People in Healthcare for 2024, marking continued recognition of Shaw as a transformative leader...
AdventHealth has named Elise MacCarroll-Wright as president and CEO of UChicago Medicine AdventHealth Hinsdale in its Great Lakes Region, effective Jan. 6, 2025.
AdventHealth has named Dave Tkachuck president/CEO for UChicago Medicine AdventHealth La Grange, effective Jan. 6.
A UChicago Medicine AdventHealth neurologist addresses the growing gap between the number of men and women diagnosed with MS.
AdventHealth has named Ryan Quattlebaum president/CEO for AdventHealth Wesley Chapel, effective Dec. 29.
Health care and government leaders celebrate the much-anticipated expansion of AdventHealth University.
Wangsness has more than 30 years of experience in health care.
‘Imagine Wholeness’ features the Grammy-winning group Take 6 and the AdventHealth Orchestra.
Bejarano will assume leadership on Dec. 15, 2024.
The 25th anniversary of ‘To Err is Human’ provides an opportunity to reflect on key learnings that have shaped the hospital system’s culture of safety.
The agreement includes ShorePoint Health Port Charlotte, Certain Assets of ShorePoint Health Punta Gorda and a free-standing Emergency Department.
AdventHealth has achieved the top spot on the Gartner Healthcare Supply Chain Top 25 for 2024.